[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370220-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370220-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","estimating-the-ovarian-cancer-ca-125-preclinical-detectable-phase-in-vivo-tumour-doubling-time-and-window-for-detection-in-early-stage-an-exploratory-analysis-of-ukctocs","Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS","","Ovarian cancer preclinical detectable phase (PCDP), defined as the interval when disease can be detected before clinical diagnosis, is poorly characterised. Exploratory analyses from the UKCTOCS used longitudinal serum CA-125 interpreted by ROCA. In postmenopausal women, PCDP duration, in-vivo tumour doubling time, and the early-stage detection window were estimated via change-point and Bayesian models, and informed benchmark values for early detection and diagnostic workflow intervals.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/estimating-the-ovarian-cancer-ca-125-preclinical-detectable-phase-in-vivo-tumour-doubling-time-and-window-for-detection-in-early-stage-an-exploratory-analysis-of-ukctocs/370220/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/estimating-the-ovarian-cancer-ca-125-preclinical-detectable-phase-in-vivo-tumour-doubling-time-and-window-for-detection-in-early-stage-an-exploratory-analysis-of-ukctocs/370220.png","ImageObject",300,407,{"name":42,"@type":43},"Emma Wilson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the ovarian cancer preclinical detectable phase (PCDP) studied here?","Question",{"text":63,"@type":64},"PCDP is the interval during which ovarian cancer is detectable prior to clinical diagnosis, before invasive disease is diagnosed.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which biomarker and algorithm were used in UKCTOCS analyses?",{"text":68,"@type":64},"The analyses used serum CA-125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA), with baseline and longitudinal blood samples.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes were estimated from the models?",{"text":72,"@type":64},"The study estimated PCDP duration, in-vivo tumour doubling time, and the window for early-stage detection from CA-125 measurements using change-point and Bayesian models.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370220,1790218371,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3848291630094,"https://eur-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","Articles   \nEstimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS  \nJacob S. Bedia,a Ian J. Jacobs,b Andy Ryan,g Aleksandra Gentry-Maharaj,b,g Matthew Burnell,g Naveena Singh,c,o Ranjit Manchanda,d,e,f,g Jatinderpal K. Kalsi,h Anne Dawnay,i Lesley Fallowﬁeld,j Alistair J. McGuire,k Stuart Campbell,l Mahesh K. B. Parmar,g Usha Menon,g,n and Steven J. Skatesa,m,n,∗  \naMGH Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA  \nbDepartment of Women’s Cancer, Elizabeth Garrett Anderson Institute for Women’s Health, UCL, London, UK cDepartment of Cellular Pathology, Barts Health NHS Trust, London, UK  \ndCentre for Cancer Screening, Prevention & Early Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, London, UK  \neDepartment of Health Services Research, Faculty of Public Health & Policy, London School of Hygiene & Tropical Medicine, London, UK fDepartment of Gynaecological Oncology, Barts Health NHS Trust, London, UK  \ngMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, UCL, London, UK hAGE Research Unit, School of Public Health, Imperial College London, London, UKiDepartment of Clinical Biochemistry, Barts Health NHS Trust, London, UK  \njSussex Health Outcomes Research and Education in Cancer (SHORE-C), Brighton and Sussex Medical School, University of Sussex, Brighton, UK  \nkLondon School of Economics and Political Science, London, UK lCreate Health, London, UK  \nmHarvard Medical School, Boston, MA, USA  \nSummary  \nBackground The ovarian cancer (OC) preclinical detectable phase (PCDP), deﬁned as the interval during which cancer is detectable prior to clinical diagnosis, remains poorly characterised. We report exploratory analyses from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) .  \nMethods In UKCTOCS between Apr-2001 and Sep-2005, 101,314 postmenopausal women were randomised to no screening (NS) and 50,625 to annual multimodal screening (MMS) (until Dec-2011) using serum CA-125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA) . All provided a baseline blood sample. Women with invasive epithelial OC diagnosed between randomisation and trial censorship (Dec-2014) in the MMS and NS arms with two or more CA-125 measurements, including one within two years of diagnosis were included. OCfree women (2:1 to cases) from the MMS arm provided information on baseline CA-125 distribution. CA-125 measurements were obtained from MMS results, secondary analysis of baseline samples, and medical records. PCDP duration and in-vivo tumour doubling time were estimated using the change-point model underlying ROCA. Early-stage (Stage I and II) PCDP was estimated from a Bayesian model for the probability of early stage given a CA-125 measurement.  \nFindings Of 541 women (2371 CA-125 measurements) with high-grade serous cancer (HGSC), 93%(504/541) secreted CA-125 into the circulation. Median CA-125 PCDP duration for clinically-diagnosed HGSC was 15.2 (IQR 13.1–16.9, 95% IPR 9.6–21.8) months, of which 11.9 (IQR 10.5–13.1, 95% IPR 7.5–16.5) months was in early stage. The median HGSC in-vivo tumour doubling time for cancers secreting CA-125 was 2.9 (IQR 2.3–3.7, 95% IPR 1.5–7.6) months.  \nInterpretation We report a comprehensive characterisation of the OC CA-125 PCDP. The 12-month window for earlystage detection and short tumour doubling time of HGSC provide a benchmark for researchers evaluating novel screening approaches including need to reduce diagnostic workup interval. Equally the ﬁndings provide urgent impetus for clinicians to reduce intervals from presentation to treatment onset.  \n*Corresponding author. MGH Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA. E-mail address: [sskates@mgh.harvard.edu](sskates@mgh.harvard.edu) (S.J. Skates).  \nnEqual contribution.  \noDeceased.  \neBioMedicine 2025;","cbCaiovQP0itlCvl","https://ap.wps.com/l/cbCaiovQP0itlCvl","pdf",729698,13,"English","# Summary\n## Background\n## Methods\n## Findings\n## Interpretation\n# Research in context\n## Evidence before this study","[{\"question\":\"What is the ovarian cancer preclinical detectable phase (PCDP) studied here?\",\"answer\":\"PCDP is the interval during which ovarian cancer is detectable prior to clinical diagnosis, before invasive disease is diagnosed.\"},{\"question\":\"Which biomarker and algorithm were used in UKCTOCS analyses?\",\"answer\":\"The analyses used serum CA-125 interpreted by the Risk of Ovarian Cancer Algorithm (ROCA), with baseline and longitudinal blood samples.\"},{\"question\":\"What outcomes were estimated from the models?\",\"answer\":\"The study estimated PCDP duration, in-vivo tumour doubling time, and the window for early-stage detection from CA-125 measurements using change-point and Bayesian models.\"}]","Estimating the ovarian cancer CA-125 preclinical detectable phase, in-vivo tumour doubling time, and window for detection in early stage: an exploratory analysis of UKCTOCS | PDF",1790187436,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/41f6f1980a3c877c6f8fb59237162aae.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36a0bde2762a42a7a68eef9e3c4f2ce9.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/da70b0fc0d83c49e85a617663b71d8e9.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d490645a0db70dabb48ae38367ecd145.webp",980,1306]